Abstract
Natural products continue to be a source of inspiration for chemists and biologists alike. The search for biologically active natural products has provided troves of information about biological processes, and natural products continue to be some of the most powerful and useful probes of biological processes available. Complex and unusual molecular architectures provide the impetus for new reaction development and push the limits of known synthetic chemistry. In addition to serving as tools for basic research, natural products represent starting points for drug discovery efforts in many cases.
This review details the impressive chemical diversity present in the family of molecules that inhibit the proteasome and other aspects of the ubiquitin-proteasome pathway. To date, over 60 natural products that inhibit the ubiquitin-proteasome pathway have been identified. Although early work recognized inhibitors of the proteasome itself, more modern research has revealed that inhibition of many aspects of this critical pathway is possible. One powerful example of this is the inhibition of the interaction between p53 and MDM2 (an E3 ubiquitin ligase). Natural product proteasome inhibitors have served as powerful tools to unravel the intricacies of the ubiquitin-proteasome and related pathways. Several of these natural products have been developed into anticancer drug candidates, and one proteasome inhibitor has already been approved for the treatment of multiple myeloma. Despite the wealth of information available about naturally occurring proteasome inhibitors and related compounds, it is clear that exciting research about this class of molecules will continue well into the future.
Keywords: Ubiquitin-proteasome pathway, inhibitors, natural products, proteasome, ubiquitin, epoxomicin, lactacystin, salinosporamide, drug discovery, natural product
Current Drug Targets
Title: Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Volume: 12 Issue: 11
Author(s): John S. Schneekloth and Craig M. Crews
Affiliation:
Keywords: Ubiquitin-proteasome pathway, inhibitors, natural products, proteasome, ubiquitin, epoxomicin, lactacystin, salinosporamide, drug discovery, natural product
Abstract: Natural products continue to be a source of inspiration for chemists and biologists alike. The search for biologically active natural products has provided troves of information about biological processes, and natural products continue to be some of the most powerful and useful probes of biological processes available. Complex and unusual molecular architectures provide the impetus for new reaction development and push the limits of known synthetic chemistry. In addition to serving as tools for basic research, natural products represent starting points for drug discovery efforts in many cases.
This review details the impressive chemical diversity present in the family of molecules that inhibit the proteasome and other aspects of the ubiquitin-proteasome pathway. To date, over 60 natural products that inhibit the ubiquitin-proteasome pathway have been identified. Although early work recognized inhibitors of the proteasome itself, more modern research has revealed that inhibition of many aspects of this critical pathway is possible. One powerful example of this is the inhibition of the interaction between p53 and MDM2 (an E3 ubiquitin ligase). Natural product proteasome inhibitors have served as powerful tools to unravel the intricacies of the ubiquitin-proteasome and related pathways. Several of these natural products have been developed into anticancer drug candidates, and one proteasome inhibitor has already been approved for the treatment of multiple myeloma. Despite the wealth of information available about naturally occurring proteasome inhibitors and related compounds, it is clear that exciting research about this class of molecules will continue well into the future.
Export Options
About this article
Cite this article as:
S. Schneekloth John and M. Crews Craig, Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway, Current Drug Targets 2011; 12 (11) . https://dx.doi.org/10.2174/138945011798109491
DOI https://dx.doi.org/10.2174/138945011798109491 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Role of Metal Ions in the Aβ Oligomerization in Alzheimers Disease and in Other Neurological Disorders
Current Alzheimer Research Suicidal Inactivation of Methemoglobin by Generation of Thiyl Radical: Insight into NAC Mediated Protection in RBC
Current Molecular Medicine Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy
Current Cancer Therapy Reviews Chemical Composition and In Vitro Neuroprotective Activity of Fibre-Type Cannabis sativa L. (Hemp)
Current Bioactive Compounds Cellomics as Integrative Omics for Cancer
Current Proteomics S100b Induces Expression of Myoglobin in APβ Treated Neuronal Cells In Vitro: A Possible Neuroprotective Mechanism
Current Aging Science An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Eremurus spectabilis, Rich Source of Isoorientin: Isolation, Quantification and Anti-Cancer Activity on SH-SY5Y Neuroblastoma Cells
Current Pharmaceutical Analysis Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line
Current HIV Research